STOCKSCOPE

Mayne Pharma (ASX: MYX) Secures $604 Million Takeover at 99% Premium. Is This a Major Turning Point?

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:4d ago
Mayne Pharma (ASX: MYX) Secures $604 Million Takeover at 99% Premium. Is This a Major Turning Point?

A $604 million takeover agreement has created a significant opportunity for Mayne Pharma Group Limited (ASX: MYX) shareholders, with Hungarian pharmaceutical group Gedeon Richter offering $6.40 per share in cash.

The proposal represents a 99.4% premium to Mayne Pharma's closing share price on 16 November 2026, highlighting the strategic value of its pharmaceutical portfolio and established US operations.

After a challenging period of acquisition negotiations and operational restructuring, the agreement could mark a decisive turning point for the Australian pharmaceutical company.

Key Numbers Behind the Acquisition

  • $604 million: Approximate equity value of the proposed acquisition, including assumed convertible note conversion and equity incentives.
  • $6.40 per share: Cash consideration, representing a 99.4% premium to the 16 November 2026 closing price of $3.21.
  • 22.14%: Combined shareholding of three major shareholders intending to support the transaction, subject to no superior proposal.
  • $95.7 million: Unaudited revenue for the September 2026 quarter.
  • 84,000 prescriptions: DistributeRx quarterly volume, representing 120% year-on-year growth.

A Major Step Towards Unlocking Shareholder Value

Under the scheme implementation deed announced on 17 November 2026, Gedeon Richter has agreed to acquire 100% of Mayne Pharma through a scheme of arrangement.

The agreement follows the termination of an earlier $7.40-per-share acquisition proposal from Cosette Pharmaceuticals and subsequent legal proceedings.

The new transaction provides a clear pathway towards delivering substantial cash consideration to shareholders.

Importantly, Richter intends to fund the acquisition entirely through existing cash resources, removing the uncertainty associated with external financing arrangements.

Mayne Pharma's board has unanimously recommended the proposal, subject to an independent expert concluding that the scheme is in shareholders' best interests and no superior proposal emerging.

Completion remains subject to regulatory, shareholder and court approvals, alongside the company's planned international business divestment.

What Stands Out to Us

The acquisition highlights the strategic importance of Mayne Pharma's established US pharmaceutical operations.

Richter already owns the estetrol franchise underlying NEXTSTELLIS, Mayne Pharma's US contraceptive product, creating a strong commercial connection between the businesses.

Bringing Mayne Pharma into Richter's broader pharmaceutical portfolio could strengthen distribution capabilities, expand its presence in women's health and create opportunities for operational efficiencies.

Although September-quarter underlying EBITDA declined 52% to $5.3 million, Mayne Pharma continues to demonstrate encouraging growth across important product categories.

The company also held $67.3 million in cash and marketable securities at 30 September 2026.

We think Richter's willingness to commit approximately $604 million demonstrates the strategic appeal of Mayne Pharma's brands, distribution network and established market position, despite recent earnings pressures.

What Mayne Pharma Is Doing Now

Mayne Pharma continues to advance its operational transformation while preparing for the proposed acquisition.

The company is progressing the $55.5 million sale of its international operations to Evaris Pharma, a transaction designed to simplify its business structure and sharpen its focus on the US market.

Its DistributeRx platform delivered approximately 84,000 prescriptions during the September quarter, representing 120% year-on-year growth.

Meanwhile, NEXTSTELLIS demand cycles increased 27%, while IMVEXXY prescription volumes rose 13%.

Mayne Pharma is also preparing to open an expanded automated pharmacy facility in Lexington, Kentucky, in early 2027.

Together, these developments highlight the company's ongoing efforts to strengthen its distribution capabilities, improve operational efficiency and expand its commercial reach.

Insight: Could Richter Unlock Greater Value From Mayne Pharma?

We think the proposed acquisition represents a positive development that recognises the strategic value of Mayne Pharma's pharmaceutical portfolio beyond its recent earnings performance. Richter's established relationship with the company, combined with its international pharmaceutical operations, creates a credible opportunity to improve commercial efficiency and strengthen the US women's health business. While declining EBITDA demonstrates that operational challenges remain, growing prescription volumes provide encouraging evidence of underlying demand. The fully funded proposal strengthens transaction certainty, although regulatory approvals and completion conditions remain important considerations.

What Happens Next?

Mayne Pharma expects its first court hearing in December 2026, followed by a shareholder meeting in late January 2027.

Implementation is targeted for mid-to-late March 2027, subject to the necessary approvals and satisfaction of transaction conditions.

The proposed $55.5 million international business divestment remains an important milestone, alongside Foreign Investment Review Board approval and US antitrust clearance.

The independent expert's report will also help shareholders assess the proposed $6.40-per-share consideration.

With a substantial takeover premium, existing strategic relationships and a fully funded acquisition proposal, Mayne Pharma has secured a significant opportunity to deliver shareholder value.

Successful completion would bring its latest corporate transformation to a conclusion while positioning its established pharmaceutical brands within Richter's larger international business.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX slides to five-month low as AI sell-off rattles global markets
Market Briefings
Market Briefings

ASX slides to five-month low as AI sell-off rattles global markets

Australian equities: what moved the ASX 200? Australian shares extended their losing streak on Friday, with the S&P/ASX 200 falling 137.8 points, or 1.58%, to close at 8,592.6. This marked...

Mark ElzayedMark Elzayed•
NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play
Technology
Technology

NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play

NEXTDC Limited ASX: NXT has delivered an encouraging upgrade to its FY27 earnings guidance, highlighting the strength of its broader data centre business despite electricity supply delays at...

Danny AadDanny Aad•
Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential
Mining
Mining

Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential

A standout 25-metre intersection grading 31.4% manganese has delivered another encouraging result for Trek Metals Limited ASX: TKM, strengthening the exploration potential of its Kuro discov...

Alison ElzayedAlison Elzayed•
EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges
Biotech & Health
Biotech & Health

EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges

EBR Systems ASX: EBR has taken another significant step towards expanding the commercial reach of its wireless heart pacing technology, with US Medicare authorities proposing national covera...

Danny AadDanny Aad•
Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches
Mining
Mining

Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches

Orion Minerals ASX: ORN has reached a significant turning point in its copper and zinc development strategy, receiving its first US$6.7 million payment from global mining group Glencore. The...

Alison ElzayedAlison Elzayed•
EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development
Biotech & Health
Biotech & Health

EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development

EMVision Medical Devices ASX: EMV is building momentum towards a potentially significant commercial breakthrough, with a fresh $306,750 government grant payment supporting the expansion of i...

Danny AadDanny Aad•
Loading more stories...